(MedPage Today) — At the American Diabetes Association annual meeting, 2-year results from the SUPPRESS-EARLY trial showed that initiating tirzepatide (Mounjaro, Zepbound) early in the course of type 2 diabetes led to substantially higher rates…
Source link : https://www.medpagetoday.com/meetingcoverage/adavideopearls/121967
Author :
Publish date : 2026-06-29 15:57:00
Copyright for syndicated content belongs to the linked Source.
